International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance

被引:8
作者
Tan, Wei Shen [1 ]
Contieri, Roberto [1 ,2 ,3 ]
Buffi, Nicolo Maria [2 ,3 ]
Lughezzani, Giovanni [2 ,3 ]
Grajales, Valentina [1 ]
Soloway, Mark [4 ]
Casale, Paolo [3 ]
Hurle, Rodolfo [3 ]
Kamat, Ashish M. [1 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA
[2] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, MI, Italy
[3] IRCCS Humanitas Res Hosp, Dept Urol, Rozzano, Italy
[4] Mem Canc Inst, Mem Hosp, Div Urol, Hollywood, FL 10065 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
non-muscle invasive bladder neoplasms; watchful waiting; risk; prognosis; QUALITY-OF-LIFE; INDIVIDUAL PATIENTS; MANAGEMENT; RECURRENT;
D O I
10.1097/JU.0000000000003639
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We sought to determine if the International Bladder Cancer Group IR-NMIBC (Intermediate-risk Nonmuscle-invasive Bladder Cancer) scoring system can predict the requirement of delayed transurethral resection of bladder tumor in low-grade nonmuscle-invasive bladder cancer managed by active surveillance.Materials and Methods: We prospectively studied recurrent low-grade Ta/T1 nonmuscle-invasive bladder cancer patients managed with active surveillance with the following characteristics: low-grade papillary nonmuscle-invasive bladder cancer, <= 5 apparent low-grade nonmuscle-invasive bladder tumors, tumor diameter <= 1 cm, absence of gross hematuria, and negative urinary cytology. Subsequent transurethral resection of bladder tumor was offered to patients who no longer met the inclusion criteria or patient choice. The ability of the International Bladder Cancer Group IR-NMIBC scoring system to predict receipt of subsequent transurethral resection of bladder tumor was determined. Multivariable Cox proportional hazards analysis was used to determine factors associated with subsequent transurethral resection of bladder tumor.Results: A total of 163 patients with low-grade Ta/T1 nonmuscle-invasive bladder cancer were included for analysis. After a median follow-up of 33 months (IQR: 21-46), transurethral resection of bladder tumor was performed on 109 patients. At landmark time point of 24 months, patients with 0 risk factors were over 2-fold more likely to continue active surveillance compared to patients with >= 3 risk factors (59% vs 24%). Multivariable Cox regression suggested that the International Bladder Cancer Group IR-NMIBC scoring system was associated with subsequent transurethral resection of bladder tumor (1-2 risk factors [HR: 1.66, 95% CI: 0.96-2.90, P = .072],>= 3 risk factors [HR: 3.21, 95% CI: 1.70-6.09, P < .001]) after adjusting for age, T stage, and sex.Conclusions: The International Bladder Cancer Group IR-NMIBC scoring system can predict the risk of subsequent transurethral resection of bladder tumor in patients with low-grade nonmuscle-invasive bladder cancer on active surveillance.
引用
收藏
页码:763 / 770
页数:8
相关论文
共 29 条
  • [1] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
    Babjuk, Marko
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Escrig, Jose L. Dominguez
    Gontero, Paolo
    Liedberg, Fredrik
    Masson-Lecomte, Alexandra
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Seisen, Thomas
    Soukup, Viktor
    Sylvester, Richard J.
    [J]. EUROPEAN UROLOGY, 2022, 81 (01) : 75 - 94
  • [2] Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes
    Catto, James W. F.
    Downing, Amy
    Mason, Samantha
    Wright, Penny
    Absolom, Kate
    Bottomley, Sarah
    Hounsome, Luke
    Hussain, Syed
    Varughese, Mohini
    Raw, Caroline
    Kelly, Phil
    Glaser, Adam W.
    [J]. EUROPEAN UROLOGY, 2021, 79 (05) : 621 - 632
  • [3] Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
    Chang, Sam S.
    Boorjian, Stephen A.
    Chou, Roger
    Clark, Peter E.
    Daneshmand, Siamak
    Konety, Badrinath R.
    Pruthi, Raj
    Quale, Diane Z.
    Ritch, Chad R.
    Seigne, John D.
    Skinner, Eila Curlee
    Smith, Norm D.
    McKiernan, James M.
    [J]. JOURNAL OF UROLOGY, 2016, 196 (04) : 1021 - 1029
  • [4] Comperat E, 2023, Non-muscle-invasive bladder cancer (TaT1 and CIS) EAU guidelines on
  • [5] Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience
    Contieri, Roberto
    Paciotti, Marco
    Lughezzani, Giovanni
    Buffi, Nicolo M.
    Frego, Nicola
    Diana, Pietro
    Fasulo, Vittorio
    Saita, Alberto
    Casale, Paolo
    Lazzeri, Massimo
    Guazzoni, Giorgio
    Hurle, Rodolfo
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (02): : 251 - 255
  • [6] Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
    Cox, Edward
    Saramago, Pedro
    Kelly, John
    Porta, Nuria
    Hall, Emma
    Tan, Wei Shen
    Sculpher, Mark
    Soares, Marta
    [J]. CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : E418 - E442
  • [7] Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
    Cumberbatch, Marcus George Kwesi
    Jubber, Ibrahim
    Black, Peter C.
    Esperto, Francesco
    Figueroa, Jonine D.
    Kamat, Ashish M.
    Kiemeney, Lambertus
    Lotan, Yair
    Pang, Karl
    Silverman, Debra T.
    Znaor, Ariana
    Catto, James W. F.
    [J]. EUROPEAN UROLOGY, 2018, 74 (06) : 784 - 795
  • [8] Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study
    Erikson, Marie Schmidt
    Petersen, Astrid Christine
    Andersen, Klaus Kaae
    Jacobsen, Frederik Krogsdal
    Mogensen, Karin
    Hermann, Gregers Gautier
    [J]. SCANDINAVIAN JOURNAL OF UROLOGY, 2020, 54 (04) : 281 - 289
  • [9] Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines
    Flaig, Thomas W.
    Spiess, Philippe E.
    Abern, Michael
    Agarwal, Neeraj
    Bangs, Rick
    Boorjian, Stephen A.
    Buyyounouski, Mark K.
    Chan, Kevin
    Chang, Sam
    Friedlander, Terence
    Greenberg, Richard E.
    Guru, Khurshid A.
    Herr, Harry W.
    Hoffman-Censits, Jean
    Kishan, Amar
    Kundu, Shilajit
    Lele, Subodh M.
    Mamtani, Ronac
    Margulis, Vitaly
    Mian, Omar Y.
    Michalski, Jeff
    Montgomery, Jeffrey S.
    Nandagopal, Lakshminarayanan
    Pagliaro, Lance C.
    Parikh, Mamta
    Patterson, Anthony
    Plimack, Elizabeth R.
    Pohar, Kamal S.
    Preston, Mark A.
    Richards, Kyle
    Sexton, Wade J.
    Siefker-Radtke, Arlene O.
    Tollefson, Matthew
    Tward, Jonathan
    Wright, Jonathan L.
    Dwyer, Mary A.
    Cassara, Carly J.
    Gurski, Lisa A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (08): : 866 - 878
  • [10] Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project
    Hurle, Rodolfo
    Lazzeri, Massimo
    Vanni, Elena
    Lughezzani, Giovanni
    Buffi, NicoloMaria
    Casale, Paolo
    Saita, Alberto
    Morenghi, Emanuela
    Forni, Giovanni
    Cardone, Pasquale
    Lista, Giuliana
    Colombo, Piergiuseppe
    Peschechera, Roberto
    Pasini, Luisa
    Zandegiacomo, Silvia
    Benetti, Alessio
    Maffei, Davide
    Vavassori, Ivano
    Guazzoni, Giorgio
    [J]. JOURNAL OF UROLOGY, 2018, 199 (02) : 401 - 405